Aduhelm May Not Be Perfect, But It May Be A Start – If Patients Can Access It
Debate At CTAD Underscores Doctors’ Dilemma
The Biogen/Eisai drug may have a disease-modifying impact on Alzheimer’s progression but the lack of published evidence is still causing prescriber reluctance and hampering reimbursement decisions.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Pfizer’s "game-changing" COVID-19 oral antiviral results; Novartis sells Roche stake; Novartis trumps productive pipeline; Bayer sees blockbuster status for hot flashes drug; and continued hesitance over Aduhelm in the US.
Following Biogen’s lead with Aduhelm, the first disease-modifying Alzheimer’s therapy approved in the US, Eisai began a rolling BLA submission for lecanemab (BAN2401) ahead of next year’s Phase III results.
Reimbursement, health policy and medical experts predicted a slow rollout ahead for Biogen's new Alzheimer's treatment at a public meeting sponsored by ICER.